BTIG initiates Smith & Nephew stock coverage with neutral rating

BTIG has initiated coverage on Smith & Nephew (NYSE:SNN) with a Neutral rating, highlighting a balanced risk and reward scenario for the London-based medical technology company. The firm praises Smith & Nephew's strong position in the $50 billion medical technology market, which is expected to grow at approximately 6% annually. The company operates across three business units, with the Orthopaedics and Sports Medicine & ENT segments being its largest revenue generators.

BTIG's RISE strategy aims to achieve 6% to 7% organic revenue compound annual growth, generate over $1 billion in free cash flow, and achieve 12% to 13% return on invested capital by 2028. Despite some concerns, such as a revenue guidance cut for fiscal 2026 and challenges in the orthopaedics market and reimbursement for wound care, the firm remains optimistic about the company's financial prospects.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.